The peptide triggers downstream signalling cascades (angiogenesis via VEGFR2, fibroblast migration via FAK-paxillin, nitric oxide system engagement) whose biological effects persist for days to weeks after the peptide itself has been cleared
80mg combined content with meaningful dosing across all compounds
Cmax of 13.28 pg/ml (predicted) vs
It has been studied in preclinical models, cell cultures, and animal research for effects across a broader range of tissue types than most peptides of comparable size, including angiogenesis, nitric oxide signaling, and tendon, ligament, and muscle healing models
However, as of the publication date of this article, no formal FDA reclassification has been finalized